Brain-on-Chips | dinhngocduy

Brain-on-Chip ( from Wyss)

Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and prion diseases (PrD) are the common type of dementia, leading to lost the brain function and death after eight years from symptoms begin.

Worldwide cost of dementia in 2018 is US$1 trillion and rise to US$ 2 trillion by 2030.

-All drugs fail in clinical trial, No Drug to Cure

Develop one drug: 14 years with its cost $2,6 billion

- 95% of drugs failed during human clinical trials.

There are two reasons for the failure of drug development:

• The first occurs when we used the 2D cell culture in the petri dish to test the potential drug candidate. Thus, the result of testing different from inside the human.

•The second occurs when the drug reaction in animal models fail to translate into the human.

The bright solution is using organs-on-chips (Occ) to emulate the human biological function for drug testing.

Brain-on-Chip: Compartment Microfluidic Chips for Neuron Coculture (Germany BMBF project funding) Collaboration with Dr. Jean-Michel. Peyrin (neurobiologist, Institute of Biology Paris-Seine, France) who founded the MicroBrain Biotech company and Neurotoxicology and Chemosensation Group, Leibniz Research Centre for Working Environment and Human Factors, TU Dortmund, Germany

Applications (Commercial Potential):

-The compartment microfluidic chip can be used to understand the dissemination of aggregated molecules from one neuron to the others and protein transport between neurons and glial cells. We sent out the chips for first ordering to Prof Tsuneya Ikezu, MD, PhD, Department of Pharmacology & Experimental Therapeutics and Neurology, Alzheimer's Disease Center, Boston University School of Medicine.

-This chip can be used to understand the mechanisms involved in the propagation of hyperphosphorylated tau and long-range BNDF-mediated signaling.